Anja Wagner

Dr. Anja Wagner


Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 April 2021 in Gut
Verified
Journal Article
Open access
PDF file
KOKasper A Overbeek
Kasper A Overbeek
ILiris levink
iris levink
BKBrechtje D M Koopmann
Brechtje D M Koopmann
FHFemme Harinck
Femme Harinck
IKIngrid C A W Konings
Ingrid C A W Konings
Marco BrunoMarco Bruno
Marco Bruno
Objective We aimed to determine the long-term yield of pancreatic cancer surveillance in hereditary predisposed high-risk individuals. Design From 2006 to 2019, we prospectively enrolled asymptomatic individuals with an estimated 10% or greater lifetime risk of pancreatic ductal adenocarcinoma (PDAC) after obligatory evaluation by a clinical geneticist and genetic testing, and subjected them to annual surveillance with both endoscopic ultrasonography (EUS) and MRI/cholangiopancreatography (MRI/MRCP) at each visit. Results 366 individuals (201 mutation-negative familial pancreatic cancer (FPC) kindreds and 165 PDAC susceptibility gene mutation carriers; mean age 54 years, SD 9.9) were followed for 63 months on average (SD 43.2). Ten individuals developed PDAC, of which four presented with a symptomatic interval carcinoma and six underwent resection. The cumulative PDAC incidence was 9.3% in the mutation carriers and 0% in the FPC kindreds (p<0.001). Median PDAC survival was 18 months (range 1–32). Surgery was performed in 17 individuals (4.6%), whose pathology revealed 6 PDACs (3 T1N0M0), 7 low-grade precursor lesions, 2 neuroendocrine tumours <2 cm, 1 autoimmune pancreatitis and in 1 individual no abnormality. There was no surgery-related mortality. EUS detected more solid lesions than MRI/MRCP (100% vs 22%, p<0.001), but less cystic lesions (42% vs 83%, p<0.001). Conclusion The diagnostic yield of PDAC was substantial in established high-risk mutation carriers, but non-existent in the mutation-negative proven FPC kindreds. Nevertheless, timely identification of resectable lesions proved challenging despite the concurrent use of two imaging modalities, with EUS outperforming MRI/MRCP. Overall, surveillance by imaging yields suboptimal results with a clear need for more sensitive diagnostic markers, including biomarkers.

27 January 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
AWAnja Wagner
Anja Wagner
SAStefan Aretz
Stefan Aretz
AAAnnika Auranen
Annika Auranen
Marco BrunoMarco Bruno
Marco Bruno
Giulia Martina CavestroGiulia Martina Cavestro
Giulia Martina Cavestro
GMGabriela Möslein
Gabriela Möslein
The scientific data to guide the management of Peutz–Jeghers syndrome (PJS) are sparse. The available evidence has been reviewed and discussed by diverse medical specialists in the field of PJS to update the previous guideline from 2010 and formulate a revised practical guideline for colleagues managing PJS patients. Methods: Literature searches were performed using MEDLINE, Embase, and Cochrane. Evidence levels and recommendation strengths were assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE). A Delphi process was followed, with consensus being reached when ≥80% of the voting guideline committee members agreed. Recommendations and statements: The only recent guidelines available were for gastrointestinal and pancreatic management. These were reviewed and endorsed after confirming that no more recent relevant papers had been published. Literature searches were performed for additional questions and yielded a variable number of relevant papers depending on the subject addressed. Additional recommendations and statements were formulated. Conclusions: A decade on, the evidence base for recommendations remains poor, and collaborative studies are required to provide better data about this rare condition. Within these restrictions, multisystem, clinical management recommendations for PJS have been formulated.

23 December 2009 in Hereditary Cancer in Clinical Practice
Verified
Journal Article
Open access
PDF file
DRDewkoemar Ramsoekh
Dewkoemar Ramsoekh
AWAnja Wagner
Anja Wagner
MLMonique E van Leerdam
Monique E van Leerdam
DDDennis Dooijes
Dennis Dooijes
CTCarli Mj Tops
Carli Mj Tops
EKErnst J Kuipers
Ernst J Kuipers
Lynch syndrome (LS) is associated with a high risk for colorectal cancer (CRC) and extracolonic malignancies, such as endometrial carcinoma (EC). The risk is dependent of the affected mismatch repair gene. The aim of the present study was to calculate the cumulative risk of LS related cancers in proven MLH1, MSH2 and MSH6 mutation carriers. The studypopulation consisted out of 67 proven LS families. Clinical information including mutation status and tumour diagnosis was collected. Cumulative risks were calculated and compared using Kaplan Meier survival analysis. MSH6 mutation carriers, both males and females had the lowest risk for developing CRC at age 70 years, 54% and 30% respectively and the age of onset was delayed by 3-5 years in males. With respect to endometrial carcinoma, female MSH6 mutation carriers had the highest risk at age 70 years (61%) compared to MLH1 (25%) and MSH2 (49%). Also, the age of EC onset was delayed by 5-10 years in comparison with MLH1 and MSH2. Although the cumulative lifetime risk of LS related cancer is similar, MLH1, MSH2 and MSH6 mutations seem to cause distinguishable cancer risk profiles. Female MSH6 mutation carriers have a lower CRC risk and a higher risk for developing endometrial carcinoma. As a consequence, surveillance colonoscopy starting at age 30 years instead of 20-25 years is more suitable. Also, prophylactic hysterectomy may be more indicated in female MSH6 mutation carriers compared to MLH1 and MSH2 mutation carriers.

1 November 2005 in Familial Cancer
Verified
Journal Article
Closed access
PDF file
AWAnja Wagner
Anja Wagner
IKIngrid van Kessel
Ingrid van Kessel
MKMieke G. Kriege
Mieke G. Kriege
CTCarli M. J. Tops
Carli M. J. Tops
JWJuul Th. Wijnen
Juul Th. Wijnen
HMHanne Meijers-Heijboer
Hanne Meijers-Heijboer

1 December 2016 in Gynecologic Oncology
Verified
Journal Article
Closed access
AGAnne Goverde
Anne Goverde
MSManon Cw Spaander
Manon Cw Spaander
HDHelena C Van Doorn
Helena C Van Doorn
HDHendrikus J Dubbink
Hendrikus J Dubbink
AOAns Mw Van Den Ouweland
Ans Mw Van Den Ouweland
LGLIMO study group
LIMO study group

17 February 2009 in Hereditary Cancer in Clinical Practice
Verified
Journal Article
Open access
PDF file
MRMarielle Wg Ruijs
Marielle Wg Ruijs
ABAnnegien Broeks
Annegien Broeks
FMFred H Menko
Fred H Menko
MAMargreet Center Ausems
Margreet Center Ausems
AWAnja Wagner
Anja Wagner
SVSenno Verhoef
Senno Verhoef
Background: CHEK2has previously been excluded as a major cause of Li-Fraumeni syndrome (LFS). One particularCHEK2germline mutation, c.1100delC, has been shown to be associated with elevated breast cancer risk. The prevalence ofCHEK2*1100delC differs between populations and has been found to be relatively high in the Netherlands. The question remains nevertheless whetherCHEK2germline mutations contribute to the Li-Fraumeni phenotype.Methods: We have screened 65 DutchTP53-negative LFS/LFL candidate patients forCHEK2germline mutations to determine their contribution to the LFS/LFL phenotype.Results: We identified six index patients with aCHEK2sequence variant, four with the c.1100delC variant and two sequence variants of unknown significance, p.Phe328Ser and c.1096-?_1629+?del.Conclusion: Our data show thatCHEK2is not a major LFS susceptibility gene in the Dutch population. However,CHEK2might be a factor contributing to individual tumour development inTP53-negative cancer-prone families.